# US 2006/0039985 A1 · Methotrexate compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0039985 A1
- Document ID: US20060039985A1
- Status: Published application
- Kind: A1
- Application number: 11/115,776
- Filed: 2005-04-27
- Published: 2006-02-23
- Earliest claimed: 2004-04-27
- Inventors: David Bennett; David Lechuga-Ballesteros
- Web page: https://patentgrep.com/patent/US20060039985A1

## CPC

- A61K 9/0075: {for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}
- A61K 9/008: {comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]}
- A61K 9/1688: {resulting in pure drug agglomerate optionally containing up to 5% of excipient}
- A61K 31/525: Isoalloxazines, e.g. riboflavins, vitamin B2
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A powder containing methotrexate particles in liquid crystal form suitable for inhalation.

## Claims

### Claim 1

A pharmaceutical formulation comprising plurality of spray dried particles, the particles comprising methotrexate in a liquid crystal state.

### Claim 2 (depends on 1)

The pharmaceutical formulation of claim 1 suitable for delivery by inhalation.

### Claim 3 (depends on 2)

The pharmaceutical formulation of claim 2 wherein the particles have a mass median diameter of less than 10 μM.

### Claim 4 (depends on 3)

The pharmaceutical formulation of claim 3 wherein the particles have a mass median diameter of less than 5 μM.

### Claim 5 (depends on 2)

The pharmaceutical formulation of claim 2 wherein the particles have a median aerodynamic diameter (MMAD) of less than 10 μM.

### Claim 6 (depends on 5)

The pharmaceutical formulation of claim 5 wherein the particles have a median aerodynamic diameter (MMAD) of less than 5 μM.

### Claim 7 (depends on 2)

The pharmaceutical formulation of claim 2 additionally comprising a pharmaceutically acceptable excipient.

### Claim 8 (depends on 7)

The pharmaceutical formulation of claim 7 wherein the excipients include at least one compound selected from the group consisting of an amino acid, a peptide, a carbohydrate, a phospholipids, a lipid, and the salt of an organic acid.

### Claim 9 (depends on 7)

The pharmaceutical formulation of claim 7 wherein the excipients include at least one compound selected from the group consisting of sucrose, mannitol, galactose, mannose, sorbose, lactose, trehalose, cyclodextrin, raffinose, maltodextrin, dextran, xylitol, a citrate salt, leucine, trileucine, human serum albumin and combinations thereof.

### Claim 10 (depends on 7)

The pharmaceutical formulation of claim 7 wherein the pharmaceutically acceptable excipient and the methotrexate are substantially both co-localized within the same particles.

### Claim 11 (depends on 7)

The pharmaceutical formulation of claim 7 wherein the pharmaceutically acceptable excipient and the methotrexate are substantially not co-localized within the same particles, but are present in different particles.

### Claim 12 (depends on 11)

The pharmaceutical formulation of claim 11 wherein the excipient particles and the methotrexate particles are of different mean diameters.

### Claim 13 (depends on 2)

The composition of claim 2, containing less than 5% degradation products.

### Claim 14

A method for preparing a formulation, the formulation comprising a liquid crystal form of methotrexate, the method comprising the steps of: (i) combining methotrexate, an optional excipient, and solvent to form a mixture; and (ii) spray drying the mixture or solution to obtain dry particles comprised of methotrexate in a liquid crystal form and the excipient, when present.

### Claim 15 (depends on 14)

The method of claim 14, wherein the spray dried formulation contains less than 5% degradation products.

### Claim 16 (depends on 14)

The method of claim 14, wherein the mixture is an aqueous solution.

### Claim 17 (depends on 14)

The method of claim 14, wherein the spray dried powder comprises particles 98% or more of which have a diameter of 10 microns or less.

### Claim 18 (depends on 14)

The method of claim 14, wherein the spray dried powder comprises particles about 90% of which have a diameter of 5 microns or less.

### Claim 19 (depends on 4)

A method for administering a formulation comprising a liquid crystal form of methotrexate to the lungs of a patient, the method comprising the steps of: (i) providing a formulation of claim 4; (ii) dispersing the formulation to form an aerosol; and (iii) delivering the aerosol to the lungs of the patient by inhalation of the aerosol by the patient.

### Claim 20 (depends on 19)

The method of claim 19 wherein delivering the aerosol to the lungs is performed employing a metered dose inhaler.
